Opposing effects of IL-2 in tumor immunotherapy: Promoting CD8 T cell growth and inducing apoptosis

Journal of Immunology

Volumn 169, Issue 4, 2002, Pages 1753-1759

  Shrikant, Protul ^a   Mescher, Matthew F ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0037103249     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.4.1753     Document Type: Article

References (43)

1. Interleukin-2: Inception, impact, and implications
2. Observations on systemic administration of autologous LAK cells and recombinant IL-2 to patients with metastatic cancer
3. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes
4. Therapy with cultured T cells: Principles revisited
5. Immunotherapy of cancer using IL-2
6. Keynote address: Perspectives on the use of interleukin-2 in cancer treatment
7. The future of interleukin-2: Enhancing therapeutic anti-cancer vaccines
8. + cytotoxic T-cell responses during chronic viral infection
9. + T cells
10. + T cell numbers are maintained during γ-herpesvirus reactivation in CD4-deficient mice
11. + T cell and IL-2-dependent mechanism
12. Viral immune evasion due to persistence of activated T cells without effector function
13. + T cells become non-responsive (anergic) following activation in the presence of costimulation
14. Activation-induced nonresponsiveness: A Th-dependent regulatory checkpoint in the CTL response
15. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis
16. Mature T lymphocyte apoptosis: Immune regulation in a dynamic and unpredictable antigenic environment
17. + T cell death
18. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo
19. Use of adoptive transfer of T-cell antigen-receptor-transgenic T cell for the study of T-cell activation in vivo
20. + T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness
21. T cell receptor antagonist peptides induce positive selection
22. Introduction of soluble protein into the class I pathway of antigen processing and presentation
23. Clinical effects and toxicity of interleukin-2 in patients with cancer
24. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
25. A novel assay for apoptosis: Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V
26. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
27. Signaling alterations in activation-induced nonresponsive CD8 T cells
28. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo
29. Clonal expansion vs functional clonal inactivation
30. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice
31. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice
32. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens
33. Role of antigen, CD8 and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL
34. Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo
35. Induction of apoptosis in mature T cells by tumor necrosis factor
36. + T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1)
37. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
38. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
39. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
40. Phenotypic analysis of antigen-specific T lymphocytes
41. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
42. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
43. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals